An interventional study of Flavonoid and Placebo in Inflammation, sponsored by Appalachian State University. Completed at 1 site in United States. Open to female participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-02-02.
Sponsored by Appalachian State University · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies in Inflammation by Appalachian State University — none open to participants now, none under way, none of them phase 3. Inflammation · Appalachian State University.
Among the 19 studies in Inflammation by Appalachian State University, this one has the largest enrollment, is one of 2 that started in 2015, is one of 19 with no phase, and was the 9th registered.
3,545 studies on the registry are indexed under Inflammation; 650 are open to participants now.
Browse Inflammation studies →None of the 19 studies in Inflammation by Appalachian State University is open now. The open studies under Inflammation, anywhere →
Of the 464 Inflammation studies recruiting now, 175 (38%) set no upper age limit and 208 (45%) stop at 75 or younger; 58 take children under 18; 166 take healthy volunteers.
This study: 18 Years to 65 Years · female · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
First in 2011; this study’s year is marked. 2 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 110 is above the median of 50 across 2,586 interventional studies indexed under Inflammation.
Median enrollment 40 across the 19 interventional studies. Of the 19 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Appalachian State University is the lead sponsor of 41 studies on the registry; 2 are open to participants now.
None of the studies under way reaches primary completion within a year.
Among the 19 studies in Inflammation by Appalachian State University, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study will measure the effect of ingesting a flavonoid-rich supplement on various biomarkers in overweight/obese women during a 12-week period. The flavonoid-rich supplement contains a mixture of flavonoids including quercetin, catechins from green tea extract, and anthocyanins from bilberry extract, and other food components that facilitate flavonoid bioactivity including fish oil, caffeine, and vitamin C.
Hypothesis: Subjects randomized to ingestion of the flavonoid-rich supplement compared to placebo will experience an increase in total urine polyphenols concentrations and shifts in blood metabolites related to increased flavonoid metabolism. Secondarily, subjects ingesting the flavonoid-rich supplement will experience a decrease in systemic inflammation and oxidative stress.
BASELINE TESTING (ASU-NCRC HUMAN PERFORMANCE LAB):
A. One week before the start of the study, subjects will report to the ASU-NCRC Human Performance Lab, be oriented to the study, and provide voluntary consent. Subjects will fill in a medical health questionnaire to verify medical history and lifestyle habits. Subjects must agree to maintain normal dietary and physical activity patterns during the 12-week intervention, and not make formal attempts to lose body weight. All other subject inclusion and exclusion criteria must be maintained during the study. Subjects will be instructed on how to record all food intake during a 3-day period prior to the start of the study (Thursday, Friday, and Sunday).
Subjects will be instructed on how to collect urine for 24-hours during the day just before the study starts. Urine collection guidelines:
B. On the first day of the study, subjects will return to the lab in a fasted state (9 or more hours with no food or beverage other than water) and turn in the 3-day food record and the 24-h urine collection sample. Height, body weight, and percent body fat (seca BIA scale) will be measured. Blood samples will be collected from an antecubital vein with subjects in the seated position by trained phlebotomists. Each blood sample will not exceed 40 ml (2.7 tablespoons). Subjects will also record responses to a 4-week retrospective symptom log. Subjects will be given flavonoid or placebo supplements for the first 4-week period, and ingest the first two supplements in the lab under supervision.
12-WEEK INTERVENTION: Subjects (N=110) will be randomized to the flavonoid supplement or placebo supplement groups for 12 weeks (thus two independent groups run in parallel with 55 subjects). Supplements will be administered in a double-blinded manner, with the code held by Reoxcyn Discoveries Group until the end of the study. The goal is for N=100 subjects to complete all phases of the study. Subjects will ingest two supplement supplements each day of the study, one before breakfast, and the second one before lunch.
Subjects will report to the Human Performance Lab at the 4- and 12-week time points in an overnight-fasted state and repeat all baseline measurements (including the 3-day food record and 24-h urine collection). The 4-week retrospective symptom logs will be filled in at pre-study, 4, 8, and 12 weeks (with the 8-week log administered via email). Subjects will be given an 8-weeks supply of the supplement after completing the 4-week lab session.
SUPPLEMENT INFORMATION:
The flavonoid-rich supplement contains a mixture of flavonoids from green tea and bilberry extracts, and quercetin. The supplement also contains food components that boost flavonoid benefits in the body including fish oil, caffeine, and vitamin C.
The daily dose will be 4 flavonoid tablets (two before breakfast, two before lunch).
Here is a detailed summary of the ingredients of the flavonoid-rich supplement (4 tablets per day):
Supplement Facts Serving size: 4 Tablets Servings per container: 30 Amount per Serving % Daily Value Calories 50 Total Carbohydrate 12 g 4% Sugars 10 g Vitamin C (as Ascorbyl Palmitate) 100 mg 167% Wild Bilberry Fruit Extract (std. min. 25% Total Anthocyanins) 156 mg ** Green Tea Leaf Extract 180 mg ** Quercetin 100 mg ** Natural Caffeine (from Coffea arabica Bean) 100 mg ** NovoOmega® Omega-3 F30 Powder (Std. 30% Omega-3 Fatty Acids (Eicosapentaenoic Acid and Docosahexaenoic Acid)) 200 mg ** * Percent Daily Values are based on a 2,000 calorie diet
** Daily Value not Established Other Ingredients: Sugar, Natural \& Artificial Flavor, Dextrose, Cellulose Gum, Sucralose, Bamboo Whole Plant Extract, Guar Gum, Xanthan Gum, Citric Acid, Malic Acid, L-Tartaric Acid Contains Fish.
In general, the flavonoid-rich chewable tablets (4 per day) will provide the equivalent quantity of flavonoids as found in 10 apples, one cup of green tea, and one-fourth cup of bilberries. Consuming 4 tablets per day will add approximately 50% more of the beneficial polyphenols typically consumed by adults.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Flavonoid supplement
Dietary Supplement: Flavonoid
Placebo
Dietary Supplement: Placebo
Drug pages: FlavonoidsStudies of FlavonoidsFlavonoids pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · FlavonolsStudies of FlavonolsFlavonols pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · Dietary FlavonoidStudies of Dietary FlavonoidDietary Flavonoid pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
Flavonoid rich supplement
Placebo
Change in Urine phenolics
24-h urine samples collected pre-study and after 12-weeks intervention
Time frame: Change from baseline urine phenolics at 12 weeks
Change in global metabolomics
Blood sample analysis for shifts in metabolites pre-study and after 12-weeks intervention
Time frame: Change from baseline global metabolomics at 12 weeks
Change in symptoms
A 4-week retrospective symptom log will be administered pre-study, 4-weeks, 8-weeks, and 12-weeks to document potential adverse gastrointestinal and mental effects.
Time frame: Change from baseline symptoms at 4-weeks, 8-weeks, 12-weeks.
Change in oxidized LDL
plasma oxidized LDL
Time frame: Change from baseline oxidized LDL at 12 weeks
Change in blood diagnostic chemistries
Comprehensive blood diagnostic chemistry panels
Time frame: Change from baseline diagnostic chemistries at 12 weeks
Change in CRP
C-reactive protein
Time frame: Change from baseline CRP at 12 weeks
Change in IL-6
Plasma IL-6
Time frame: Change from baseline IL-6 at 12 weeks
Change in MCP-1
Plasma MCP-1
Time frame: Change from baseline MCP-1 at 12 weeks
Change in FRAP
Plasma FRAP
Time frame: Change from baseline FRAP at 12 weeks
Plan to share: Yes — Data will be shared through the Human Metabolome Database (HMDB), other public web sites, and publication in the scientific literature.
No publications or documents are linked to this record.
Ran from Aug 2015 to primary completion in Jun 2016, 10 months.
Of 882 non-industry interventional studies with no phase under Inflammation, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 36. This study's 10 months is below that.
Counting every sponsor, half of 929 studies reached it within 17 months; a quarter within 8 and three quarters within 36.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Flavonoids · Flavonols · Dietary Flavonoid
Appalachian State University